150 related articles for article (PubMed ID: 12657873)
41. Pharmacologic interventions for the management of critical bleeding.
Voils S
Pharmacotherapy; 2007 Sep; 27(9 Pt 2):69S-84S. PubMed ID: 17723110
[TBL] [Abstract][Full Text] [Related]
42. Use of recombinant factor VIIa as a rescue treatment for intractable bleeding following repeat aortic arch repair.
Stratmann G; Russell IA; Merrick SH
Ann Thorac Surg; 2003 Dec; 76(6):2094-7. PubMed ID: 14667657
[TBL] [Abstract][Full Text] [Related]
43. Low-dose recombinant activated factor VII in massively transfused trauma patients with coagulopathy.
Bauzá G; Hirsch E; Burke P; Quillen K
Transfusion; 2007 Apr; 47(4):749-51. PubMed ID: 17381636
[No Abstract] [Full Text] [Related]
44. [Activated recombinant factor VII (Novoseven) in multiple trauma patients: an outcome analysis].
Grinţescu I; Tulbure D; Mirea L
Chirurgia (Bucur); 2006; 101(6):615-24. PubMed ID: 17283837
[TBL] [Abstract][Full Text] [Related]
45. Potential role of recombinant factor VIIa as a hemostatic agent.
Hedner U; Erhardtsen E
Clin Adv Hematol Oncol; 2003 Feb; 1(2):112-9. PubMed ID: 16224390
[TBL] [Abstract][Full Text] [Related]
46. Effective treatment of severe bleeding due to acquired thrombocytopathia by single dose administration of activated recombinant factor VII.
Meijer K; Sieders E; Slooff MJ; de Wolf JT; van der Meer J
Thromb Haemost; 1998 Jul; 80(1):204-5. PubMed ID: 9684815
[No Abstract] [Full Text] [Related]
47. The clinical and laboratory response to recombinant factor VIIA in trauma and surgical patients with acquired coagulopathy.
McMullin NR; Kauvar DS; Currier HM; Baskin TW; Pusateri AE; Holcomb JB
Curr Surg; 2006; 63(4):246-51. PubMed ID: 16843774
[TBL] [Abstract][Full Text] [Related]
48. Administration of recombinant factor VIIa for the management of massive bleeding due to uterine atonia in the post-placental period.
Tanchev S; Platikanov V; Karadimov D
Acta Obstet Gynecol Scand; 2005 Apr; 84(4):402-3. PubMed ID: 15762974
[No Abstract] [Full Text] [Related]
49. Preemptive use of recombinant activated factor VII: many questions but few answers.
Samama CM
Can J Anaesth; 2006 Apr; 53(4):336-8. PubMed ID: 16575029
[No Abstract] [Full Text] [Related]
50. 'Last-ditch' use of recombinant factor VIIa in patients with massive haemorrhage is ineffective.
Clark AD; Gordon WC; Walker ID; Tait RC
Vox Sang; 2004 Feb; 86(2):120-4. PubMed ID: 15023181
[TBL] [Abstract][Full Text] [Related]
51. Recombinant Factor VIIa in blunt pelvic trauma.
Hurst T; Blanckley S; Forrest M
Anaesthesia; 2005 Dec; 60(12):1244-5; author reply 1245. PubMed ID: 16288629
[No Abstract] [Full Text] [Related]
52. Recombinant activated factor VII: its mechanism of action and role in the control of hemorrhage.
Allen GA; Hoffman M; Roberts HR; Monroe DM
Can J Anaesth; 2002 Dec; 49(10):S7-14. PubMed ID: 12546000
[TBL] [Abstract][Full Text] [Related]
53. The use of recombinant activated factor VII in congenital and acquired von Willebrand disease.
Franchini M; Veneri D; Lippi G
Blood Coagul Fibrinolysis; 2006 Nov; 17(8):615-9. PubMed ID: 17102646
[TBL] [Abstract][Full Text] [Related]
54. Four-factor prothrombin complex concentrate for urgent reversal of vitamin K antagonists in patients with major bleeding.
Quinlan DJ; Eikelboom JW; Weitz JI
Circulation; 2013 Sep; 128(11):1179-81. PubMed ID: 23935012
[No Abstract] [Full Text] [Related]
55. Use of recombinant factor VIIa for refractory hemorrhage during extracorporeal membrane oxygenation.
Dominguez TE; Mitchell M; Friess SH; Huh JW; Manno CS; Ravishankar C; Gaynor JW; Tabbutt S
Pediatr Crit Care Med; 2005 May; 6(3):348-51. PubMed ID: 15857537
[TBL] [Abstract][Full Text] [Related]
56. The emerging role of recombinant-activated factor VII in neurocritical care.
Fewel ME; Park P
Neurocrit Care; 2004; 1(1):19-29. PubMed ID: 16174895
[TBL] [Abstract][Full Text] [Related]
57. Use of recombinant activated factor VII after axillofemoral bypass grafting.
Cheng CA; Ho AM
Anaesth Intensive Care; 2006 Jun; 34(3):375-8. PubMed ID: 16802495
[TBL] [Abstract][Full Text] [Related]
58. Recent developments in topical thrombins.
Kessler CM; Ortel TL
Thromb Haemost; 2009 Jul; 102(1):15-24. PubMed ID: 19572062
[TBL] [Abstract][Full Text] [Related]
59. [Use of recombinant factor VIIa for the control of massive bleeding caused by uterine hypotonia in post-placental period].
Tanchev S; Platikanov V; Markova S; Slavov N; Bogdanova A; Dimitrova D
Akush Ginekol (Sofiia); 2004; 43(1):16-20. PubMed ID: 15168648
[TBL] [Abstract][Full Text] [Related]
60. Critical bleeding in vascular surgery: expanding the indication of recombinant activated factor VII.
Tawfick WA; Tawfik S; Hynes N; Mahendran B; Sultan S
Vascular; 2006; 14(1):32-7. PubMed ID: 16849021
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
